Abstract | BACKGROUND: METHODS: RESULTS: With the FA regimen, the survival rate was 80.0% (8 of 10 patients) for a mean follow-up of 10 years. Two patients died due to multidrug resistance, and two patients subsequently developed recurrent disease. The two patients with recurrent disease were successfully salvaged again with the MEA regimen. The toxicity of the FA regimen was evaluated in 78 cycles. Myelosuppression seemed to be the dose-limiting toxicity, and the incidences of World Health Organization Grade 4 leukocytopenia and thrombocytopenia were 6.4% and 3.8%, respectively, of 78 cycles. CONCLUSIONS: Although etoposide-containing chemotherapy is currently the most effective and well-tolerated regimen for patients with high-risk GTTs, 20-30% of patients develop resistance to etoposide-containing regimens. Salvage combination chemotherapy with FA is effective for these patients with refractory disease, and the toxicity is predictable and manageable.
|
Authors | Hideo Matsui, Kiyomi Suzuka, Yoshinori Iitsuka, Koji Yamazawa, Naotake Tanaka, Akira Mitsuhashi, Katsuyoshi Seki, Souei Sekiya |
Journal | Cancer
(Cancer)
Vol. 95
Issue 5
Pg. 1051-4
(Sep 01 2002)
ISSN: 0008-543X [Print] United States |
PMID | 12209690
(Publication Type: Journal Article)
|
Copyright | Copyright 2002 American Cancer Society. |
Chemical References |
- Dactinomycin
- Fluorouracil
|
Topics |
- Adult
- Dactinomycin
(administration & dosage)
- Drug Resistance, Multiple
- Female
- Fluorouracil
(administration & dosage)
- Humans
- Leukopenia
(chemically induced)
- Neoplasm Recurrence, Local
(drug therapy)
- Pregnancy
- Retrospective Studies
- Risk Factors
- Salvage Therapy
- Survival Analysis
- Thrombocytopenia
(chemically induced)
- Trophoblastic Neoplasms
(drug therapy, pathology)
- Uterine Neoplasms
(drug therapy, pathology)
|